0.2% (OTC), developed by Alcon Laboratories Inc. Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC), will be distributed in the U.S. by Glenmark Therapeutics Inc., USA. According to ...

Glenmark Pharmaceuticals Inc., USA (Glenmark), a research-led, global pharmaceutical company, has received final approval by the United States Food & Drug Administration (FDA) for olopatadine ...